{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T05:15:36Z","timestamp":1770527736358,"version":"3.49.0"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,12,9]],"date-time":"2019-12-09T00:00:00Z","timestamp":1575849600000},"content-version":"vor","delay-in-days":222,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006095","name":"Helse S\u00f8r-\u00d8st RHF","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006095","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005416","name":"Norges Forskningsr\u00e5d","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005416","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Psychoneuroendocrinology"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.psyneuen.2019.01.001","type":"journal-article","created":{"date-parts":[[2019,1,6]],"date-time":"2019-01-06T04:23:35Z","timestamp":1546748615000},"page":"87-95","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Adipokine levels are associated with insulin resistance in antipsychotics users independently of BMI"],"prefix":"10.1016","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2226-2445","authenticated-orcid":false,"given":"Trude S. Jahr","family":"Vedal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nils Eiel","family":"Steen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K\u00e5re I.","family":"Birkeland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingrid","family":"Dieset","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elina J.","family":"Reponen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jannicke F.","family":"Laskemoen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linn","family":"R\u00f8devand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9783-548X","authenticated-orcid":false,"given":"Ingrid","family":"Melle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ole A.","family":"Andreassen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Espen","family":"Molden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8368-6332","authenticated-orcid":false,"given":"Erik G.","family":"J\u00f6nsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.psyneuen.2019.01.001_bib0005","doi-asserted-by":"crossref","DOI":"10.1515\/hmbci-2017-0065","article-title":"Cardiometabolic effects of psychotropic medications","author":"Abosi","year":"2018","journal-title":"Horm. Mol. Biol. Clin. Investig."},{"key":"10.1016\/j.psyneuen.2019.01.001_bib0010","series-title":"Diagnostic and Statistical Manual of Mental Disoders","author":"American Psychiatric","year":"1995"},{"key":"10.1016\/j.psyneuen.2019.01.001_bib0015","doi-asserted-by":"crossref","first-page":"e16","DOI":"10.1111\/dme.12359","article-title":"The effects of antipsychotic switching on diabetes in chronic schizophrenia","volume":"31","author":"Arnoldy","year":"2014","journal-title":"Diabet. Med."},{"key":"10.1016\/j.psyneuen.2019.01.001_bib0020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0094112","article-title":"Almost all antipsychotics result in weight gain: a meta-analysis","volume":"9","author":"Bak","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.psyneuen.2019.01.001_bib0025","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1097\/YCO.0b013e32835d9efb","article-title":"Polypharmacy for schizophrenia","volume":"26","author":"Ballon","year":"2013","journal-title":"Curr. Opin. Psychiatry"},{"key":"10.1016\/j.psyneuen.2019.01.001_bib0030","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.psyneuen.2015.03.012","article-title":"Plasma adiponectin levels in schizophrenia and role of second-generation antipsychotics: a meta-analysis","volume":"56","author":"Bartoli","year":"2015","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.psyneuen.2019.01.001_bib0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eplepsyres.2013.08.016","article-title":"Metabolic and endocrine effects of valproic acid chronic treatment","volume":"107","author":"Belcastro","year":"2013","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.psyneuen.2019.01.001_bib0040","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/JCP.0b013e31819b95fc","article-title":"Hormonal markers of metabolic dysregulation in patients with severe mental disorders after olanzapine treatment under real-life conditions","volume":"29","author":"Birkenaes","year":"2009","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.psyneuen.2019.01.001_bib0045","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.pnpbp.2018.01.004","article-title":"Atypical antipsychotics, insulin resistance and weight; a meta-analysis of healthy volunteer studies","volume":"83","author":"Burghardt","year":"2018","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.psyneuen.2019.01.001_bib0050","doi-asserted-by":"crossref","first-page":"643","DOI":"10.3389\/fnins.2017.00643","article-title":"Molecular mechanisms of antipsychotic drug-induced diabetes","volume":"11","author":"Chen","year":"2017","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.psyneuen.2019.01.001_bib0055","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1111\/j.1464-5491.2005.01628.x","article-title":"Diabetic ketoacidosis associated with aripiprazole","volume":"22","author":"Church","year":"2005","journal-title":"Diabet. Med."},{"key":"10.1016\/j.psyneuen.2019.01.001_bib0060","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1185\/03007995.2014.908280","article-title":"A review of real-world data on the effects of aripiprazole on weight and metabolic outcomes in adults","volume":"30","author":"Citrome","year":"2014","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.psyneuen.2019.01.001_bib0065","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/j.cell.2018.05.046","article-title":"Genomic dissection of bipolar disorder and schizophrenia, including 28 subphenotypes","volume":"173","author":"Bipolar Disorder and Schizophrenia Working Group of the Psychiatric Genomics Consortium","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.psyneuen.2019.01.001_bib0070","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1016\/S0140-6736(15)00241-X","article-title":"Bipolar disorder","volume":"387","author":"Grande","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.psyneuen.2019.01.001_bib0075","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.schres.2016.09.026","article-title":"Meta-analysis of glucose tolerance, insulin, and insulin resistance in antipsychotic-naive patients with nonaffective psychosis","volume":"179","author":"Greenhalgh","year":"2017","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.psyneuen.2019.01.001_bib0080","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.2217\/pgs.09.102","article-title":"Sex-specific differences in side effects of psychotropic drugs: genes or gender?","volume":"10","author":"Haack","year":"2009","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.psyneuen.2019.01.001_bib0085","doi-asserted-by":"crossref","first-page":"252","DOI":"10.2174\/1871530315666150623092031","article-title":"Weight gain and metabolic changes during treatment with antipsychotics and antidepressants","volume":"15","author":"Himmerich","year":"2015","journal-title":"Endocr. Metab. Immune Disord. Drug Targets"},{"key":"10.1016\/j.psyneuen.2019.01.001_bib0090","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s40264-017-0543-0","article-title":"Second-generation antipsychotics and metabolic side effects: a systematic review of population-based studies","volume":"40","author":"Hirsch","year":"2017","journal-title":"Drug Saf."},{"key":"10.1016\/j.psyneuen.2019.01.001_bib0095","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.schres.2007.11.026","article-title":"Impact of atypical antipsychotic therapy on leptin, ghrelin, and adiponectin","volume":"100","author":"Jin","year":"2008","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.psyneuen.2019.01.001_bib0100","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.jpsychires.2009.11.007","article-title":"Relationship between body mass index and insulin resistance in patients treated with second generation antipsychotic agents","volume":"44","author":"Kim","year":"2010","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.psyneuen.2019.01.001_bib0105","doi-asserted-by":"crossref","first-page":"S64","DOI":"10.1192\/bjp.184.47.s64","article-title":"Diabetes mellitus and schizophrenia: historical perspective","volume":"47","author":"Kohen","year":"2004","journal-title":"Br. J. Psyciatry Suppl."},{"key":"10.1016\/j.psyneuen.2019.01.001_bib0110","doi-asserted-by":"crossref","first-page":"857","DOI":"10.4088\/JCP.v65n0619","article-title":"A survey of reports of quetiapine-associated hyperglycemia and diabetes mellitus","volume":"65","author":"Koller","year":"2004","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.psyneuen.2019.01.001_bib0115","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1093\/bmb\/ldv017","article-title":"Antipsychotic medication in schizophrenia: a review","volume":"114","author":"Lally","year":"2015","journal-title":"Br. Med. Bull."},{"key":"10.1016\/j.psyneuen.2019.01.001_bib0120","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1089\/met.2011.0123","article-title":"The impact of leptin and adiponectin on incident type 2 diabetes is modified by sex and insulin resistance","volume":"10","author":"Lilja","year":"2012","journal-title":"Metab. Syndr. Relat. Disord."},{"key":"10.1016\/j.psyneuen.2019.01.001_bib0125","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1515\/hmbci-2013-0053","article-title":"The role of leptin\/adiponectin ratio in metabolic syndrome and diabetes","volume":"18","author":"Lopez-Jaramillo","year":"2014","journal-title":"Horm. Mol. Biol. Clin. Investig."},{"key":"10.1016\/j.psyneuen.2019.01.001_bib0130","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1592\/phco.28.9.1198","article-title":"Diabetic ketoacidosis associated with aripiprazole","volume":"28","author":"Makhzoumi","year":"2008","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.psyneuen.2019.01.001_bib0135","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1089\/met.2010.0053","article-title":"Metabolic syndrome in severe mental disorders","volume":"9","author":"Ohaeri","year":"2011","journal-title":"Metab. Syndr. Relat. Disord."},{"key":"10.1016\/j.psyneuen.2019.01.001_bib0140","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/S0140-6736(15)01121-6","article-title":"Schizophrenia","volume":"388","author":"Owen","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.psyneuen.2019.01.001_bib0145","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1177\/2045125312464385","article-title":"The prevalence and mechanisms of metabolic syndrome in schizophrenia: a review","volume":"3","author":"Papanastasiou","year":"2013","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"10.1016\/j.psyneuen.2019.01.001_bib0150","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.comppsych.2006.03.008","article-title":"Generalizability studies of the global assessment of functioning-split version","volume":"48","author":"Pedersen","year":"2007","journal-title":"Compr. Psychiatry"},{"key":"10.1016\/j.psyneuen.2019.01.001_bib0155","doi-asserted-by":"crossref","first-page":"108","DOI":"10.24869\/psyd.2017.108","article-title":"Causes of mortality in schizophrenia: an updated review of European studies","volume":"29","author":"Piotrowski","year":"2017","journal-title":"Psychiatr. Danub."},{"key":"10.1016\/j.psyneuen.2019.01.001_bib0160","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3389\/fpsyt.2014.00137","article-title":"Increased mortality in schizophrenia due to cardiovascular disease \u2013 a non-systematic review of epidemiology, possible causes, and interventions","volume":"5","author":"Ringen","year":"2014","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.psyneuen.2019.01.001_bib0165","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.schres.2010.07.012","article-title":"Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis","volume":"123","author":"Rummel-Kluge","year":"2010","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.psyneuen.2019.01.001_bib0170","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0182088","article-title":"The risk of new-onset diabetes in antidepressant users \u2013 a systematic review and meta-analysis","volume":"12","author":"Salvi","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.psyneuen.2019.01.001_bib0175","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.schres.2016.04.051","article-title":"Adiposity-independent hypoadiponectinemia as a potential marker of insulin resistance and inflammation in schizophrenia patients treated with second generation antipsychotics","volume":"174","author":"Sapra","year":"2016","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.psyneuen.2019.01.001_bib0180","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/j.bbrc.2014.07.005","article-title":"Atypical antipsychotics induce both proinflammatory and adipogenic gene expression in human adipocytes in vitro","volume":"450","author":"Sarvari","year":"2014","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.psyneuen.2019.01.001_bib0185","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.4088\/JCP.08r04392","article-title":"Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review","volume":"70","author":"Simon","year":"2009","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.psyneuen.2019.01.001_bib0190","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1093\/schbul\/sbp034","article-title":"Neurocognitive dysfunction in bipolar and schizophrenia spectrum disorders depends on history of psychosis rather than diagnostic group","volume":"37","author":"Simonsen","year":"2011","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.psyneuen.2019.01.001_bib0195","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/978-3-642-25761-2_8","article-title":"Antipsychotics in the treatment of bipolar disorder","volume":"212","author":"Singh","year":"2012","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.psyneuen.2019.01.001_bib0200","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.eurpsy.2009.01.001","article-title":"How can antipsychotics cause Diabetes Mellitus? Insights based on receptor-binding profiles, humoral factors and transporter proteins","volume":"24","author":"Starrenburg","year":"2009","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.psyneuen.2019.01.001_bib0205","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/acps.12439","article-title":"The prevalence and predictors of type two diabetes mellitus in people with schizophrenia: a systematic review and comparative meta-analysis","volume":"132","author":"Stubbs","year":"2015","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.psyneuen.2019.01.001_bib0210","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.psyneuen.2015.09.026","article-title":"Are leptin levels increased among people with schizophrenia versus controls? A systematic review and comparative meta-analysis","volume":"63","author":"Stubbs","year":"2016","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.psyneuen.2019.01.001_bib0215","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.2337\/db13-0430","article-title":"Antipsychotic-induced insulin resistance and postprandial hormonal dysregulation independent of weight gain or psychiatric disease","volume":"62","author":"Teff","year":"2013","journal-title":"Diabetes"},{"key":"10.1016\/j.psyneuen.2019.01.001_bib0220","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1186\/1471-244X-11-197","article-title":"Association between second-generation antipsychotics and newly diagnosed treated diabetes mellitus: does the effect differ by dose?","volume":"11","author":"Ulcickas Yood","year":"2011","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.psyneuen.2019.01.001_bib0225","doi-asserted-by":"crossref","first-page":"472","DOI":"10.4088\/JCP.v69n0320","article-title":"Major changes in glucose metabolism, including new-onset diabetes, within 3 months after initiation of or switch to atypical antipsychotic medication in patients with schizophrenia and schizoaffective disorder","volume":"69","author":"van Winkel","year":"2008","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.psyneuen.2019.01.001_bib0230","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.4088\/JCP.14r09635","article-title":"Prevalence and predictors of type 2 diabetes mellitus in people with bipolar disorder: a systematic review and meta-analysis","volume":"76","author":"Vancampfort","year":"2015","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.psyneuen.2019.01.001_bib0235","doi-asserted-by":"crossref","first-page":"Itc1","DOI":"10.7326\/AITC201503030","article-title":"In the clinic. Type 2 diabetes","volume":"162","author":"Vijan","year":"2015","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.psyneuen.2019.01.001_bib0240","doi-asserted-by":"crossref","first-page":"121","DOI":"10.24869\/psyd.2017.121","article-title":"Diabetic ketoacidosis associated with antipsychotic drugs: case reports and a review of literature","volume":"29","author":"Vuk","year":"2017","journal-title":"Psychiatr. Danub."},{"key":"10.1016\/j.psyneuen.2019.01.001_bib0245","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.2337\/diacare.27.6.1487","article-title":"Use and abuse of HOMA modeling","volume":"27","author":"Wallace","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.psyneuen.2019.01.001_bib0250","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.pnpbp.2012.10.010","article-title":"Adjunctive effects of aripiprazole on metabolic profiles: comparison of patients treated with olanzapine to patients treated with other atypical antipsychotic drugs","volume":"40","author":"Wang","year":"2013","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.psyneuen.2019.01.001_bib0255","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S2215-0366(15)00007-3","article-title":"The epidemiology of diabetes in psychotic disorders","volume":"2","author":"Ward","year":"2015","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.psyneuen.2019.01.001_bib0260","series-title":"Daily Defined Dose: Definitions and General Considerations","author":"WHO, C.C.f.D.S.M","year":"2016"},{"key":"10.1016\/j.psyneuen.2019.01.001_bib0265","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.cca.2012.12.007","article-title":"Role of leptin and adiponectin in insulin resistance","volume":"417","author":"Yadav","year":"2013","journal-title":"Clin. Chim. Acta"},{"issue":"Suppl. 7","key":"10.1016\/j.psyneuen.2019.01.001_bib0270","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1038\/ijo.2008.233","article-title":"Physiological and pathophysiological roles of adiponectin and adiponectin receptors in the integrated regulation of metabolic and cardiovascular diseases","volume":"32","author":"Yamauchi","year":"2008","journal-title":"Int. J. Obes."}],"container-title":["Psychoneuroendocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306453018310278?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306453018310278?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T17:03:16Z","timestamp":1759683796000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306453018310278"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":54,"alternative-id":["S0306453018310278"],"URL":"https:\/\/doi.org\/10.1016\/j.psyneuen.2019.01.001","relation":{},"ISSN":["0306-4530"],"issn-type":[{"value":"0306-4530","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adipokine levels are associated with insulin resistance in antipsychotics users independently of BMI","name":"articletitle","label":"Article Title"},{"value":"Psychoneuroendocrinology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.psyneuen.2019.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}